SCHEMBL2997500

SCHEMBL2997500

CCOC(=O)c1c(C(F)(F)F)c2cc(-c3ccc(C(F)(F)F)cn3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGES O14684 3/20 0.39
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
SCN9A Q15858 2/20 0.38
POLB P06746 1/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.36
MAOB P27338 1/20 0.36
THRB P10828 2/20 0.35
GCK P35557 1/20 0.35
ALOX5AP P20292 1/20 0.35
FOS P01100 1/20 0.34
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001790 0.93 KDM4E (0.40) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3001004 0.91 KDM4E (0.39) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3006452 0.91 KDM4E (0.39) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3008051 0.91 KDM4E (0.39) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3000835 0.91 KMT2A (0.43) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3010510 0.90 PTGES (0.38) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL334166 0.90 PTGES (0.40) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL3001794 0.89 PTGES (0.45) PTGESPPARGPPARA
SCHEMBL3005514 0.89 PTGES (0.38) KDM4EL3MBTL1PTGESPPARGPPARA
SCHEMBL2997573 0.89 ALOX5AP (0.44) KDM4EL3MBTL1PTGESPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100197687-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197687-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, TPH1 KDM4E 1317/4885L3MBTL1 2062/4885PTGES 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.